HC Wainwright Raises Tyra Biosciences (NASDAQ:TYRA) Price Target to $32.00

Tyra Biosciences (NASDAQ:TYRA) had its price objective raised by HC Wainwright from $30.00 to $32.00 in a research report sent to investors on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

Other analysts have also issued reports about the stock. Wedbush restated an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a research report on Friday, October 25th. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their target price for the company from $22.00 to $31.00 in a research report on Friday, October 18th. Piper Sandler initiated coverage on shares of Tyra Biosciences in a research report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price target for the company. Finally, Oppenheimer upped their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, September 19th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $31.40.

Tyra Biosciences Stock Performance

Shares of Tyra Biosciences stock opened at $16.68 on Monday. The stock has a market capitalization of $880.80 million, a PE ratio of -9.87 and a beta of 1.01. Tyra Biosciences has a 52-week low of $10.60 and a 52-week high of $29.60. The company has a 50-day simple moving average of $22.61 and a two-hundred day simple moving average of $19.89.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.09. As a group, equities research analysts forecast that Tyra Biosciences will post -1.53 EPS for the current fiscal year.

Insider Activity

In other news, CEO Todd Harris sold 5,698 shares of the stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $24.31, for a total value of $138,518.38. Following the sale, the chief executive officer now owns 1,496,729 shares of the company’s stock, valued at approximately $36,385,481.99. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last quarter, insiders have sold 61,403 shares of company stock valued at $1,582,774. 15.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new stake in shares of Tyra Biosciences in the 3rd quarter valued at about $311,000. Perceptive Advisors LLC raised its position in Tyra Biosciences by 50.5% during the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock worth $16,108,000 after buying an additional 338,208 shares during the last quarter. Ally Bridge Group NY LLC purchased a new position in Tyra Biosciences during the 2nd quarter worth approximately $4,232,000. HighVista Strategies LLC purchased a new position in shares of Tyra Biosciences during the 2nd quarter valued at approximately $257,000. Finally, Ensign Peak Advisors Inc purchased a new position in shares of Tyra Biosciences during the 2nd quarter valued at approximately $3,047,000. 84.14% of the stock is currently owned by institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.